Qube Research & Technologies (QRT)’s Global X Funds Global X HealthTech ETF HEAL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-246
Closed -$7.39K 3885
2024
Q3
$7.39K Hold
246
﹤0.01% 3063
2024
Q2
$6.46K Sell
246
-1,373
-85% -$37.4K ﹤0.01% 3002
2024
Q1
$46.2K Sell
1,619
-100
-6% -$2.85K ﹤0.01% 3522
2023
Q4
$52.2K Sell
1,719
-67
-4% -$1.8K ﹤0.01% 3306
2023
Q3
$49.2K Sell
1,786
-1,606
-47% -$51.4K ﹤0.01% 2870
2023
Q2
$221K Buy
3,392
+2,760
+437% +$96K ﹤0.01% 1748
2023
Q1
$22.2K Sell
632
-197
-24% -$7.08K ﹤0.01% 2299
2022
Q4
$28.8K Buy
829
+11
+1% +$387 ﹤0.01% 2204
2022
Q3
$28K Sell
818
-66
-7% -$2.45K ﹤0.01% 2251
2022
Q2
$31K Sell
884
-455
-34% -$16.9K ﹤0.01% 2207
2022
Q1
$58K Sell
1,339
-1,341
-50% -$58.1K ﹤0.01% 2165
2021
Q4
$133K Buy
+2,680
New +$139K ﹤0.01% 2077

Other funds holding HEAL

Qube Research & Technologies (QRT)'s HEAL Position: Q4 2024 in Review

Qube Research & Technologies (QRT) sold out of Global X Funds Global X HealthTech ETF (HEAL) in Q4 2024, closing a stake of 246 shares — an estimated $7.39K sold.

Qube Research & Technologies (QRT) first reported a position in HEAL in Q4 2021 and held it in 12 quarters. The position peaked at $221K in Q2 2023. 28 funds tracked by Wall St. Rank hold HEAL as of Q4 2024.

  • Qube Research & Technologies (QRT) reported no remaining Global X Funds Global X HealthTech ETF position as of Q4 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 246 Global X Funds Global X HealthTech ETF shares in Q4 2024, an estimated $7.39K.
  • Qube Research & Technologies (QRT) first reported a position in Global X Funds Global X HealthTech ETF in Q4 2021 and held it in 12 quarters.
  • Qube Research & Technologies (QRT)'s Global X Funds Global X HealthTech ETF position peaked at $221K in Q2 2023.
  • 28 funds tracked by Wall St. Rank held Global X Funds Global X HealthTech ETF as of Q4 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2024, filed 14 Feb 2025.